MedTrace Logo

Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology

NCT03948724 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 411

Last updated 2025-08-17

No results posted yet for this study

Summary

The aim of this therapeutic education program is to reduce the apparition of immune-related Adverse Event with patients treated with ICI

Conditions

Interventions

BEHAVIORAL

Therapeutic education program

Patient will have 5 educational therapy workshops. The first educational therapy workshops will be realized at cycle 1 and the last one within 25 weeks after starting treatment

BEHAVIORAL

Usual Information

Patient receive usual informations

Sponsors & Collaborators

  • Institut Cancerologie de l'Ouest

    lead OTHER

Principal Investigators

  • Nathalie Beaumont · INSTITUT DE CANCEROLOGIE DE L'OUEST

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-11
Primary Completion
2023-08-04
Completion
2024-08-22

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03948724 on ClinicalTrials.gov